Landing Biotech, Inc.

New England Deaconess Hospital Corporation

Thrombolytic Science, LLC

Liu, Jianning

Jian-ning Liu

Victor Gurewich

John Noel Williams

Paolo Sarmientos

Massimiliano Pagani

The present invention provides pladin (plasma anti-diabetic nucb2 peptide) polypeptide and functional equivalent thereof that are useful for treating diabetes. The present invention provides a method of treating diabetes by administering to a subject nesfatin-1, pladin, or a functional equivalent thereof. The present invention also provides a method of treating diabetes by administering to subject plasmin inhibitors.

Plasma anti-diabetic NUCB2 peptide (pladin) and uses thereof

It has now been discovered that certain mutant forms of pro-urokinase ('pro-UK'), such as so-called pro-UK mutant 'M5' (Lys&#x2192;His), perform in the manner of pro-UK in lysing &#x201c;bad&#x201d; blood clots (those clots that occlude blood vessels), while sparing hemostatic fibrin in the so-called &#x201c;good&#x201d; blood clots (those clots that seal wounds, e.g., after surgery or other tissue injury). Thus, these pro-UK mutants are excellent and safe thrombolytic agents. These advantages allow them to be used in a variety of new methods, devices, and compositions useful for thrombolysis and treating various cardiovascular disorders in clinical situations where administration of other known thrombolytic agents has been too risky or even contraindicated.

Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots

The invention relates to thrombolytically active pro-urokinase (pro-UK) mutants comprising the amino acid sequence of native pro-UK, but including a mutation which causes the pro-UK mutants to induce less fibrinogenolysis and non-specific plasminogen activation than native pro-UK, to have at least a 10-fold lower intrinsic activity than native pro-UK, and to have substantially the same fibrin promotion and thrombolytic activity after plasmin activation compared to native pro-UK when administered to a patient.

Pro-urokinase mutants

Growing community of inventors

Brighton, MA, United States of America

Jian-ning Liu